ArticleJournal of the American Academy of Dermatology2023
Tofacitinib therapy for alopecia areata is not associated with adverse events during COVID-19 infection.
Soundos Youssef et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.